Teleologically, the mammalian brain has evolved to be the central component of life. It co-ordinates afferent and efferent neural pathways, integrates neurohormonal responses and, in humans, produces higher cortical effects that augment developmental and protective processes [1] . Despite this vital role for human survival, the brain is profoundly vulnerable to injury and is in many ways set up to fail with devastating consequences for the patient. Central to this thesis is the anatomical and functional relationship of the brain within its protective enclosures and the impact caused by traumatic brain injury (TBI).
Described 300 years ago by Monroe and Kellie, the non-compliant nature of the skull and associated tentorial cavities renders the non-compressible brain susceptible to sharp increases in intracranial pressure (ICP) for small increases in intracranial volume. This inverse relationship defines intracranial elastance, where exhaustion of a critical pressure/volume threshold results in reductions in cerebral blood flow and substrate delivery to a level where irreversible neuronal damage and death ensues [2] .
The complexity of elastance exhaustion is compounded by variations in the adaptive capacity of brain compartments; heterogeneity of primary brain injury, secondary ischaemic-hypoxic insults and age-related changes in brain volume [3] .
What has perplexed clinicians for decades is how to measure, quantify and modulate this relationship when there is no validated method of measuring intracranial elastance.
The measurement of ICP in TBI has become standard as the principal metric for clinical practice. However, ICP is a surrogate index of intracranial elastance. As with any surrogate measurement, it does not reflect the complexity of a pathophysiological relationship and is subject to measurement inaccuracies and confounding bias [4] .
Defining or applying a critical ICP threshold to direct targeted treatment is primarily based on associations between persistent intracranial hypertension and mortality [5] . The validation of an ICP 'dose' or 'burden' has evolved primarily through expert opinion, single-centre observational and cohort studies [6] . There are wide variations in methods of ICP monitoring, with and without the application of multimodal monitoring to define biochemical and metabolic perturbations relating to the ICP 'dose' [7] .
The early editions of the Brain Trauma Foundation (BTF) guidelines for the management of TBI presented the limited evidence-base for ICP monitoring, including indications, methods and treatment thresholds [8, 9]. A consistent statement was that there was insufficient high-quality evidence to make level I recommendations for ICP monitoring and therapies to treat intracranial hypertension. Nevertheless, the 2000 edition included a clinical practice guideline describing an algorithm to treat intracranial hypertension, arbitrarily defined as an ICP > 20-25 mmHg and a cerebral perfusion pressure (CPP) < 70 mmHg [10] .
The rapid adoption of this algorithm became widespread, perhaps reflecting clinician uncertainty and the lack of clinical practice guidelines for the management of TBI. However, evidence of adverse outcomes, specifically extracranial complications, associated with aggressive targeting of ICP and CPP thresholds emerged, prompting a reassessment of treatment thresholds. The initial treatment algorithm was removed from subsequent editions of the BTF guidelines, pending high-quality randomised controlled trials (RCTs) and consensus statements to inform the revision of treatment thresholds and therapies [11, 12] .
Designing and conducting an interventional RCT to compare treatment strategies aimed at reducing intracranial hypertension and reducing mortality requires three key elements: (1) the intervention needs to be biologically effective is improving intracranial elastance by reducing both intracranial pressure and volume; (2) the ICP treatment threshold at which patients are randomised needs to be pragmatic and representative of elastance failure at a point where clinical salvage is both safe and effective; (3) the deployment of the intervention needs to be timed to provide the optimal chance of survival. These considerations were integral in the design of two landmark RCTs comparing decompressive craniectomy to current ICP-specific medical therapy.
In the DECRA trial, patients with diffuse TBI were randomised to undergo either decompressive craniectomy or continued second-tier medical therapy when ICP > 20 mmHg for more than 15 mins within a 1-h period, within 72 h of injury-designed to assess early, pre-emptive decompressive craniectomy in patients with less severe TBI [13] .
In the RESCUEicp trial, patients with diffuse and mass lesion-associated TBI with refractory ICP > 25 mmHg for 1-12 h were randomised to undergo decompressive craniectomy or continued third-tier medical therapydesigned to target decompressive craniectomy in patients with refractory intracranial hypertension-the more usual clinical scenario for this intervention [14] .
Both trials reported significant reductions in ICP associated with decompressive craniectomy compared to medical therapy. While there was no significant reduction in mortality observed in DECRA, there was a 22% reduction in mortality associated with decompressive craniectomy in RESCUEicp. However, both trials reported more "unfavourable" functional outcomes 6 months after injury in patients who underwent decompressive craniectomy.
Both trials addressed the three intervention principles defined above: (1) decompressive craniectomy consistently and effectively reduces ICP, thereby improving intracranial elastance; (2) the two ICP thresholds are widely used by clinicians and recommended by clinical practice guidelines and (3) the intervention was tested at two time-critical periods representing 'real-life' clinical scenarios.
The results of both trials inform both clinical practice and treatment guidelines: decompressive craniectomy effectively improved intracranial elastance in patients with severe TBI and intracranial hypertension at a critical ICP threshold between 15-30 mmHg. However, for those patients who survived both early and late decompressive craniectomy, functional outcome was worse than in patients who underwent medical therapy. This may be explained by cephalad movement of the brain and resultant stretch-induced neuronal injury once the cranium was removed [15] .
That a critical ICP threshold exits for patients to survive is not in question. This critical threshold has been revised in the 4th edition of the BTF guidelines to 22 mmHg, although this recommendation predated the publication of the RESCUEicp results and is based on lower-quality evidence [16] . On balance, this threshold should be interpreted as the "best" evidence to date to deliver ICP-specific therapies in a relatively safe and effective manner to reduce mortality.
However, what is emerging from new evidence is that reducing ICP below a critical threshold, however defined or recommended, may not be the key determinant in producing the optimal patient-centred outcome-i.e., how the patient survives, feels and functions [17, 18] .
How clinicians interpret this will depend on whether the clinical imperative is to produce short-term improvements in measured physiological parameters that may reduce mortality or whether a more conservative, expectant strategy may result in better longer-term functional survival, recognising that a substantial proportion of these patients will die.
The consequences of severe disability are prolonged and profound on survivors, caregivers and society and the quality of survival may be more important than reducing mortality. This must be the imperative when interpreting clinical practice recommendations for the treatment of an individual patient.
